AMP Amphion Innovations Plc

RNS Number:4021S
Amphion Innovations PLC
10 October 2005





    Amphion Innovations PLC Acquires a 30% stake in Medical Imaging Company



London, UK, 10 October 2005: Amphion Innovations PLC ("Amphion"), the developer
of life sciences businesses, has invested $1 million in Supertron Technologies,
Inc taking Amphion's stake to approximately 30% on a fully diluted basis.
Supertron is a private US business developing high performance medical imaging
products that are able to dramatically improve the imaging capabilities of an
MRI scanner.  These scanners address the rapidly expanding opportunities that
are developing in the clinical and pre-clinical global MRI imaging markets,
valued at approximately $6 billion.



Supertron's products dramatically improve the imaging capabilities of
conventional MRI scanners.  The products greatly enhance the MRI image quality,
reduce scan time in existing scanners and greatly lower the cost.  Supertron is
also targeting emerging MRI research applications in the fields of molecular
imaging, image-guided therapeutics, image-guided surgery, and orthopaedics
imaging. The Company is currently developing a number of next-generation MRI
products in neuro imaging and pre-clinical imaging. In addition, the Company,
with Harvard University as its partner, has won a $2.0 million Advance
Technology Grant to accelerate the development of advanced MRI neuro-imaging.



Amphion also announces today the appointment of Richard Hullihen as new CEO of
Supertron. Mr. Hullihen is a 25 year veteran of the medical imaging industry.
While working at GEC-Picker International and Marconi Medical Systems, Mr
Hullihen held a variety of technology development and leadership positions in
their MRI and Healthcare Information Systems businesses in bringing new
technologies to global product markets.  Mr Hullihen will replace the interim
CEO Mr Joseph Flicek, managing director of Amphion, who will remain on the
Board. Robert Bertoldi, president of Amphion, will also join the Supertron Board
as Chairman.



Richard Hullihen, the new CEO of Supertron, said: "Amphion's strong experience
in the imaging marketplace and its unique approach to growing life sciences
businesses will help Supertron in its quest to become a successful participant
in this strong growth marketplace."



Richard Morgan, CEO of Amphion, added: "Amphion has had considerable previous
success in the medical imaging industry with the successful formation and growth
of Vortech Data, which was acquired by Kodak for $130 million.  Richard Hullihen
is a key appointment for the business and his experience in this industry and
proven leadership qualities are just what Supertron needs at this stage of its
development."



Enquiries:


Amphion Innovations PLC           44 (0) 20 7016 8821
Richard C.E. Morgan, Chief Executive Officer
Robert Bertoldi, President and CFO         +1 212 210 6201

Financial Dynamics        44 (0) 20 7831 3113
Ben Atwell / John Gilbert





Notes to editors



About Amphion

Amphion Innovations plc recently listed on the AIM Exchange in London under the
symbol AMP.  Amphion's business is the formation, financing, management and
development of life science and technology companies, working in partnership
with corporations, governments, universities and entrepreneurs seeking to
commercialise their intellectual property.





www.amphionplc.com





About Supertron Technologies Inc

Supertron Technologies, Inc. a spin-out from Columbia University in New York and
based in Newark, New Jersey, develops, manufactures and markets electronic
components and systems based on cryo-cooling and high temperature
superconductors' technologies for Magnetic Resonance Imaging (MRI).  The Company
is targeting clinical and pre-clinical applications for neurological, cardiac,
drug discovery, and image guided therapy applications.  Supertron's products
will be used in a variety of clinical applications for the diagnosis and staging
of disease, and the monitoring of therapeutics effects in pre-clinical studies
in drug discovery.  Supertron has Federal and State grants in-hand, supporting
its market leading MRI developments.



For further information on the company the please visit www.supertron.com or
contact Richard Hullihen on +1 973 639 1112 extension 108.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ACQDDLFBEBBBFBZ

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024